website - https://3spine.com/
3Spine raises US$33 million in Series C funding round (SpinalNewsInternational)
3Spine has raised US$33 million in an oversubscribed Series C private offering, the proceeds of which will be used to fund a Phase 2 clinical study of its BalancedBack total joint replacement procedure in the US.
The company’s MOTUS device, the implant used in the BalancedBack total joint replacement procedure, replaces the function of the disc and facet joints through a posterior approach.
According to 3Spine, the procedure broadly addresses leg pain, back pain, and spinal instability, while correcting posture and restoring freedom of movement by reconstructing the functional spinal unit. The company states that its technology is the only 1:1 replacement for lumbar spinal fusion.
MOTUS received breakthrough device designation by the US Food and Drug Administration (FDA) in September 2020 and in January 2022, the American Medical Association assigned a CPT code to track outpatient utilisation of lumbar total joint replacement as a new procedure.
Phase 1 clinical outcomes are published and 3Spine is currently enrolling a 150-patient prospective...
